Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00444353 · ClinicalTrials.gov registry record · Phase 3

DL6049 Versus Cosmoplast in the Treatment of Nasolabial Fold Wrinkles, Long Term Follow-up

A Phase 3 study, sponsored by Bausch Health Americas.

Completed
Registry status
Phase 3
Development phase
240
Enrollment target

NCT00444353 is a Phase 3 study that has completed, run by Bausch Health Americas. The registered enrollment target is 240 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00444353, a Phase 3 study, has completed, sponsored by Bausch Health Americas.

COMPLETED
Registry status
Phase 3
Development phase
240 participants
Enrollment target

Study Summary

This study is being undertaken to: * evaluate the degree of correction attainable with DL6049 (injectable poly-L-lactic acid)compared to a commercially available CosmoPlast™ Collagen Implant in the treatment of dermal nasolabial fold wrinkles at 13 months following the last application of study treatment. * Document the types and incidence of adverse events reported with DL6049 (injectable poly-L-lactic acid)compared with CosmoPlast™ Collagen Implant. Long term adverse events will be assessed for an additional 12 months following discharge from the main study in subjects treated with DL6049.

Interventions

  • DEVICE DL6049 (injectable poly-L-lactic acid)

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2004-08
Est. Completion 2007-01
Phase Phase 3

Sponsor

Bausch Health Americas

168 total trials

What the Registry Record Tells You About NCT00444353

The ClinicalTrials.gov registry entry for NCT00444353 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which DL6049 (injectable poly-L-lactic acid) is the first listed.

NCT00444353 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00444353 about?

NCT00444353 is a clinical study titled "DL6049 Versus Cosmoplast in the Treatment of Nasolabial Fold Wrinkles, Long Term Follow-up". This study is being undertaken to: * evaluate the degree of correction attainable with DL6049 (injectable poly-L-lactic acid)compared to a commercially available CosmoPlast™ Collagen Implant in the treatment of dermal nasolabial fold wrinkles at 13 months following the last application of study tre...

What is the current status of trial NCT00444353?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2004-08. Estimated completion is 2007-01.

What interventions are being tested in trial NCT00444353?

The interventions under investigation include: DL6049 (injectable poly-L-lactic acid) (DEVICE).

Who is sponsoring clinical trial NCT00444353?

This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.